Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Cancers Originate from Somatic Mutations in a Single Cell02:21

Cancers Originate from Somatic Mutations in a Single Cell

14.4K
Cancer arises from mutations in the critical genes that allow healthy cells to escape cell cycle regulation and acquire the ability to proliferate indefinitely. Though originating from a single mutation event in one of the originator cells, cancer progresses when the mutant cell lines continue to gain more and more mutations, and finally, become malignant. For example, chronic myelogenous leukemia (CML) develops initially as a non-lethal increase in white blood cells, which progressively...
14.4K
Loss of Tumor Suppressor Gene Functions01:12

Loss of Tumor Suppressor Gene Functions

5.7K
Tumor suppressor genes are normal genes that can slow down cell division, repair DNA mistakes, or program the cells for apoptosis in case of irreparable damage. Hence, they play an essential role in preventing the proliferation of damaged cells.
When the tumor suppressor genes develop mutations or are lost, cells start growing out of control, leading to cancer. However, a single functional copy of the tumor suppressor gene is enough for the cells to maintain their normal functions and cell...
5.7K
Mutations01:39

Mutations

94.0K
Overview
94.0K
Mutations01:35

Mutations

42.5K
Mutations are changes in the sequence of DNA. These changes can occur spontaneously or they can be induced by exposure to environmental factors. Mutations can be characterized in a number of different ways: whether and how they alter the amino acid sequence of the protein, whether they occur over a small or large area of DNA, and whether they occur in somatic cells or germline cells.
Chromosomal Alterations Are Large-Scale Mutations
While point mutations are changes in a single nucleotide in...
42.5K
Cancer-Critical Genes II: Tumor Suppressor Genes01:05

Cancer-Critical Genes II: Tumor Suppressor Genes

9.3K
Genes usually encode proteins necessary for the proper functioning of a healthy cell. Mutations can often cause changes to the gene expression pattern, thereby altering the phenotype.
When the function of certain critical genes, especially those involved in cell cycle regulation and cell growth signaling cascades, gets disrupted, it upsets the cell cycle progression. Such cells with unchecked cell cycles start proliferating uncontrollably and eventually develop into tumors.
Such genes that act...
9.3K
Abnormal Proliferation02:23

Abnormal Proliferation

5.0K
Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...
5.0K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Treatment Outcomes of Adult B-Cell Acute Lymphoblastic Leukemia with Post-Transplant Relapse in the Era of Immunotherapeutic Agents.

Transplantation and cellular therapy·2026
Same author

Atezolizumab for relapsed/refractory extranodal NK/T-cell lymphoma: the phase II NCCH1903/ATTACK trial.

Blood advances·2026
Same author

Drivers of temporal improvement in CAR T-cell therapy for large B-cell lymphoma: a Japanese nationwide registry analysis.

Blood advances·2026
Same author

Decreased renal function predicts severe cytokine release syndrome after CAR-T-cell therapy for large B-cell lymphoma.

British journal of haematology·2026
Same author

Donor selection for patients with HLA-homozygous haplotypes in allogeneic hematopoietic stem cell transplantation.

Annals of hematology·2026
Same author

Impact of antiviral therapies on survival in patients with HHV-6B encephalitis after cord blood transplantation: a real-world study.

Bone marrow transplantation·2026
Same journal

[Rinsho ketsueki] The Japanese journal of clinical hematology·2026
Same journal

[Rinsho ketsueki] The Japanese journal of clinical hematology·2026
Same journal

[Rinsho ketsueki] The Japanese journal of clinical hematology·2026
Same journal

[Recent advances in pathogenesis, diagnosis, and therapeutic strategies for POEMS syndrome].

[Rinsho ketsueki] The Japanese journal of clinical hematology·2026
Same journal

[Recent advances in management of systemic AL amyloidosis].

[Rinsho ketsueki] The Japanese journal of clinical hematology·2026
Same journal

[Treatment strategies for relapsed or refractory multiple myeloma: proposals for optimal treatment sequencing].

[Rinsho ketsueki] The Japanese journal of clinical hematology·2026
See all related articles

Related Experiment Video

Updated: Dec 19, 2025

Author Spotlight: Advancements in Molecular Biomarker Testing for Non-Squamous Non-Small Cell Lung Cancer
07:59

Author Spotlight: Advancements in Molecular Biomarker Testing for Non-Squamous Non-Small Cell Lung Cancer

Published on: September 8, 2023

1.5K

[Genetic alterations and lymphoma].

Kota Yoshifuji1, Keisuke Kataoka1

  • 1Division of Molecular Oncology, National Cancer Research Institute.

[Rinsho Ketsueki] the Japanese Journal of Clinical Hematology
|June 9, 2020
PubMed
Summary
This summary is machine-generated.

Genetic profiling reveals distinct alterations in malignant lymphomas, improving diagnosis and prognostication. These genetic insights are crucial for developing targeted therapies for lymphoma treatment.

Keywords:
Genetic alterationMalignant lymphomaNext-generation sequencing

More Related Videos

Enhancing Tumor Content through Tumor Macrodissection
10:04

Enhancing Tumor Content through Tumor Macrodissection

Published on: February 12, 2022

11.8K
Comparative Lesions Analysis Through a Targeted Sequencing Approach
08:16

Comparative Lesions Analysis Through a Targeted Sequencing Approach

Published on: November 5, 2019

7.1K

Related Experiment Videos

Last Updated: Dec 19, 2025

Author Spotlight: Advancements in Molecular Biomarker Testing for Non-Squamous Non-Small Cell Lung Cancer
07:59

Author Spotlight: Advancements in Molecular Biomarker Testing for Non-Squamous Non-Small Cell Lung Cancer

Published on: September 8, 2023

1.5K
Enhancing Tumor Content through Tumor Macrodissection
10:04

Enhancing Tumor Content through Tumor Macrodissection

Published on: February 12, 2022

11.8K
Comparative Lesions Analysis Through a Targeted Sequencing Approach
08:16

Comparative Lesions Analysis Through a Targeted Sequencing Approach

Published on: November 5, 2019

7.1K

Area of Science:

  • Hematology
  • Oncology
  • Genetics

Background:

  • Malignant lymphomas are heterogeneous lymphoid malignancies with diverse clinical, histological, and molecular characteristics.
  • Traditional subclassification relied on morphology and immune phenotype, but next-generation sequencing has revealed distinct genetic alterations within subtypes.
  • Recent WHO classifications incorporate genetic alterations like MYC, BCL2, and BCL6 rearrangements, defining new entities such as high-grade B-cell lymphoma.

Purpose of the Study:

  • To provide a comprehensive overview of genetic alterations across various malignant lymphoma subtypes.
  • To clarify the similarities and differences in genetic profiles among different lymphoma types.
  • To highlight the significance of genetic alterations in lymphoma diagnosis, prognostication, and therapeutic strategies.

Main Methods:

  • Review of accumulating evidence and recent studies on genetic profiling in malignant lymphomas.
  • Analysis of next-generation sequencing data to identify mutations, copy number alterations, and structural variations.
  • Integration of genetic findings with current WHO classifications and clinical data.

Main Results:

  • Distinct genetic alterations, including specific gene rearrangements (MYC, BCL2, BCL6), are identified in various lymphoma subtypes.
  • Genetic profiling enhances prognostic accuracy beyond clinical factors alone.
  • Ongoing development of targeted anti-cancer agents based on identified genetic alterations.

Conclusions:

  • Genetic alterations are pivotal in understanding the heterogeneity of malignant lymphomas.
  • Genetic profiling offers improved diagnostic and prognostic capabilities for lymphomas.
  • Exploiting genetic alterations is key to developing novel and effective therapeutic strategies for lymphoma patients.